Compounds > nanofin
Page last updated: 2024-11-06

nanofin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

nanofin: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID68843
CHEMBL ID2104431
SCHEMBL ID25816
MeSH IDM0052556

Synonyms (69)

Synonym
BB 0254893
nanophin
nsc-7513
nanofin
nanophine
naniopinum
504-03-0
lupetidine
piperidine,6-dimethyl-
wln: t6mtj b1 f1
nsc7513
nanophyn
2,6-lupetidine
lupetidin
2,6-dimethylpiperidine
piperidine, 2,6-dimethyl-
nanofine [inn-french]
einecs 207-981-6
nanofina [inn-spanish]
brn 0079827
nanofin [inn]
nanofinum [inn-latin]
nsc 63890
nsc-63890
nsc63890
STK386773
AKOS000118813
naniopine
pharmakon1600-01301019
nsc-760379
nsc760379
2,6-dimethyl-piperidine
5-20-04-00180 (beilstein handbook reference)
nanofine
nanofinum
unii-329i5805bp
nanofina
329i5805bp ,
FT-0648872
FT-0647456
PS-3668
AB02692
CHEMBL2104431
S4992
CCG-213660
AB01326529-02
AM81283
AKOS016038932
SCHEMBL25816
AB76289
CS-4799
2,6-dimethyl piperidine
DTXSID8048527
mfcd00005986
STR03569
HY-B1191
AB01326529_03
J-507521
F2190-0336
SR-01000944275-1
sr-01000944275
NCGC00263473-02
Q4596811
F10355
BRD-A21276153-001-01-1
HMS3886E09
(2r,6r)-2,6-dimethylpiperidine;hydrochloride
EN300-19581
Z104474330
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (80.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.69

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index29.69 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index34.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (29.69)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
gamma-aminobutyric acid
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.. gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.		1.9610amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid		human metabolite;
neurotransmitter;
Saccharomyces cerevisiae metabolite;
signalling molecule
pentamine
pentamine: RN given refers to parent cpd; structure in Merck		6.9310
galantamine
Galantamine: A benzazepine derived from norbelladine. It is found in GALANTHUS and other AMARYLLIDACEAE. It is a cholinesterase inhibitor that has been used to reverse the muscular effects of GALLAMINE TRIETHIODIDE and TUBOCURARINE and has been studied as a treatment for ALZHEIMER DISEASE and other central nervous system disorders.. galanthamine : A benzazepine alkaloid isolated from certain species of daffodils.		1.9610benzazepine alkaloid fundamental parent;
benzazepine alkaloid;
organic heterotetracyclic compound;
tertiary amino compound		antidote to curare poisoning;
cholinergic drug;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
plant metabolite
piperidines
Piperidines: A family of hexahydropyridines.		3.0550
ConditionIndicatedRelationship StrengthStudiesTrials
Dermatitis, Eczematous
[description not available]		01.9310
Lichen Simplex Chronicus
[description not available]		01.9310
Eczema
A pruritic papulovesicular dermatitis occurring as a reaction to many endogenous and exogenous agents (Dorland, 27th ed).		06.9310
Neurodermatitis
An extremely variable eczematous skin disease that is presumed to be a response to prolonged vigorous scratching, rubbing, or pinching to relieve intense pruritus. It varies in intensity, severity, course, and morphologic expression in different individuals. Neurodermatitis is believed by some to be psychogenic. The circumscribed or localized form is often referred to as lichen simplex chronicus.		06.9310
Blood Pressure, High
[description not available]		01.9310
Hypertension
Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.		06.9310